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1. Introduction
Vasculitis is the general term used to describe diseases associated with inflammation of the
blood vessels. This inflammation results in end-organ ischemia and damage with life-
threatening consequences. Treatment is tailored to the type of vasculitis the patient has,
prognostic features and disease severity. Two main treatment phases are recognized: induction
of remission, and maintenance of remission. In this chapter we will focus on the treatment of
ANCA-associated vasculitis (AAV), namely: Granulomatosis with polyangiitis (GPA),
formerly Wegener’s Granulomatosis; Eosinophilic granulomatosis with polyangiitis (EGPA),
formerly Churg-Strauss Syndrome, and Microscopic Polyangiitis (MPA). Patients with
Polyarteritis nodosa (PAN) were included in the initial therapeutic trials of these diseases,
therefore some of the studies results have been applied to that population as well.
We introduce first the historical use of glucocorticoids, which are uniformly incorporated in
the treatment protocols of therapeutic trials. Cyclophosphamide is recommended for the
induction of remission in AAV, and in particular for generalized and severe disease. CY‐
CLOPS, a trial of oral versus intravenous cyclophosphamide, demonstrated that intravenous
dosing was as effective in inducing remission with a reduced cumulative dose, and with fewer
episodes of leucopenia, but in long-term follow-up relapse was more common in the intrave‐
nous treatment group. NORAM compared the use of methotrexate compared to oral cyclo‐
phosphamide for induction of remission in patients with limited GPA, and concluded that
methotrexate was nearly as effective as cyclosphosphamide in achieving remission, but in
long-term follow-up more corticosteroids and further immunosuppressive agents were
required. More recently, rituximab use for the induction of remission was studied in the RAVE
and RITUXVAS clinical trials. Rituximab was proven to be effective as cyclophosphamide, but
without a reduction in the rate of infection as had been expected. Plasma exchange in combi‐
nation with oral cyclophosphamide for patients with severe renal involvement significantly
decreases the risk of end-stage renal disease compared to intravenous steroids and oral
cyclophosphamide, but without a significant difference in patient survival.
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Maintenance of remission is typically with oral cyclophosphamide, azathioprine or metho‐
trexate, with demonstrated efficacy in the CYCAZAREM and WEGENT studies. Leflunomide
is also effective, and mycophenolate mofetil is less effective than azathioprine but is an
alternative agent should the others not be tolerated. Etanercept therapy does not have a role
in maintenance therapy given its inefficacy and toxicity in patients exposed to cyclophospha‐
mide. Other anti-TNF agents, rituximab, Intravenous Immunoglobulin (IVIg), 15-Deoxysper‐
gualin, antithymocyte globulin and alemtuzumab (CAMPATH-1H) have shown some benefit
for refractory or relapsing disease and require further evaluation.
We conclude the chapter by discussing the use of trimethoprim-sulfamethoxazole (T/S) use in
localized disease, as well as a specific focus on the treatment evidence in EGPA with and
without poor prognostic factors.
2. ANCA-associated vasculitis (AAV)
AAV refers to primary forms of vasculitis targeting the small and medium sized arteries. These
were initially differentiated on the basis of clinical features in the 1990 American College of
Rheumatology (ACR) classification [1-4]. Further refinements to the classification criteria and
new nomenclature have evolved from the initial classification criteria. In 1994, the Chapel Hill
Consensus Conference group incorporated vessel size and pathological features to define the
different primary vasculitides. They also introduced the use of antibodies to discriminate
between vasculitis of the small vessels [5]. Anti-neutrophil cytoplasmic antibodies (ANCA)
were initially described in 1985 in patients with segmental necrotizing and crescentic glomer‐
ulonephritis [6] but were later identified in patients with GPA, EGPA and MPA, and are
associated with these conditions with high sensitivity and specificity [7].
There are two major types of ANCA recognized by indirect immunofluorescence (IIF). The
perinuclear pattern, or P-ANCA, is characterized by immunofluorescence seen at the periph‐
ery of the nucleus of alcohol-fixed neutrophils. The cytoplasmic pattern, or C-ANCA, is
characterized by diffuse staining of the cytoplasm. C-ANCA has a specificity for proteinase 3
(PR3), most frequently associated with GPA. P-ANCA has a specificity for myeloperoxidase
(MPO), and is most commonly seen in MPA and EGPA.
Although the etiopathogenesis of AAV is not yet well understood, immune system dysregu‐
lation and abnormal inflammatory responses ensue. Therapies which alter immune system
signaling and response are used to halt perpetuation of the inflammatory response to prevent
end-organ damage and suppress disease activity.
3. Outcomes without treatment and determining prognosis
Because these diseases have a high mortality rate (82% of mortality in GPA at one year
without treatment) [8] and relapse frequently (38% of patients with AAV will experience
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a relapse within 5 years despite treatment) [9] treatment protocols have reflected the need
to  obtain  rapid  control  of  disease  activity  and  maintain  long-term  immunosuppression
while  reducing  drug  toxicity.  This  is  the  basis  for  an  induction  phase  of  treatment  to
achieve remission followed by a maintenance phase to reduce the risk of relapse. Guille‐
vin  et  al.  developed  the  Five  Factor  Score  [10]  to  identify  factors  associated  with  poor
prognosis at the time of diagnosis. They initially analysed 342 patients with MPA, EGPA
and PAN, and the five factors associated with increased mortality were: renal failure with
creatinine greater than 140 μmol/L, proteinuria greater than 1 gram/day, cardiac involve‐
ment,  central  nervous  system  involvement,  or  severe  gastro-intestinal  involvement.  In
patients with none of these features, the 5 year survival rate was 88.1%. With 1 of these
features, the 5 year survival rate declined to 74.1%, and with 2 or more of these features
the survival rate was only 54.1%. The analysis of a larger group of 1108 patients with GPA,
MPA, EGPA and PAN in 2009 [11] resulted in the identification of new prognosis factors
associated with an increase in 5-year mortality rate. These include age > 65 years, cardiac
involvement, gastro-intestinal involvement, and renal failure with creatinine >150 μmol/L.
The  presence  of  ear,  nose  and  throat  symptoms  in  patients  with  GPA  and  EGPA  is
associated with a lower relative risk of death.
4. Categorization of disease severity to guide initial treatment agent
As reflected in the European League Against Rheumatism (EULAR) treatment guidelines
[12] the initial immunosuppressive agent choice is dictated by the extent and severity of
the disease. The European Vasculitis Study (EUVAS) disease categorisation [13] separates
disease  severity  into  localized  disease,  early  systemic  disease,  generalized,  severe  and
refractory disease.
Category Definition
Localised Upper and/or lower respiratory tract disease without any other systemic involvement or
constitutional symptoms
Early Systemic Any, without organ-threatening or life-threatening disease
Generalised Renal or other organ threatening disease, serum creatinine <500 μmol/liter (5.6 mg/dl)
Severe Renal or other vital organ failure, serum creatinine "/>500 μmol/litre (5.6 mg/dl)
Refractory Progressive disease unresponsive to glucocorticoids and cyclophosphamide
Table 1. Categorization of disease severity to guide initial treatment in anti-neutrophilic cytoplasmic antibodies
(ANCA)-associated vasculitis [13]
We will now review in detail the evidence for the agents recommended in these treatment
guidelines, as well as new evidence arising since their development.
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5. Induction of remission
5.1. Glucocorticoids
Efficacy: Glucocorticoids are the first line treatment to rapidly control inflammation and
prevent further organ damage in patients with active AAV. There is no trial evidence to
support the use, dose or route of steroids traditionally used in AAV but certainly experience
has solidified their clinical use. In all the randomized trials glucocorticoids were used in
combination with immunosuppressants and is it not possible to know their effect alone. A
report in 1957 of 17 patients with PAN revealed that the use of glucocorticoids alone lead to
80% survival at 12 months compared to 64% in an untreated group [14]. However the superi‐
ority of cortisone was not maintained at 3 years [14, 15].
In randomized controlled studies of remission induction, prednisone is started at 1 mg/kg then
tapered to a low dose (e.g. 5 mg at 18 months in CYCLOPS) [16] or completely stopped at 12
months (NORAM) [17] or even 6 months (WGET [18], RAVE [19]). The complete weaning of
steroids is not necessarily desirable as shown by a meta-analysis done by Walsh et al [20].
Continuation of low dose prednisone (5-7.5 mg/day) was associated with a lower relapse rate
of 14% (95%CI 10-19%) compared to a relapse rate of 43% (95%CI 33-52%) in those with
complete glucocorticoid discontinuation.
The European Vasculitis Study group (EUVAS) guidelines for the treatment of AAV [12]
indicate that high dose prednisolone or prednisone at 1 mg/kg be used for the first month, then
tapered to no less than 15 mg at 3 months and 10 mg or lower during the maintenance phase
of treatment. In instances where rapid control of disease is necessary, parenteral methylpred‐
nisolone (1 g daily for 3 days) should be used in addition to oral glucocorticoids.
A clinical trial currently in progress named ‘plasma exchange and glucocorticoid dosing in the
treatment of ANCA-associated vasculitis’ (PEXIVAS) (ClinicalTrials.gov Identifier:
NCT00987389) will address the question of dose and tapering schedule of glucocorticoids. The
trial design will compare the standard dosing of glucocorticoids (similar to the recommenda‐
tions of EUVAS) compared to a reduced dose regimen. All patients will receive between 1 and
3 g of intravenous methylprednisolone over 1 to 3 days, then daily oral glucocorticoid, which
may consist of prednisone or prednisolone and administered through a weight-based protocol.
Based on body weight, all participants will receive either 50, 60 or 75 mg/day of oral gluco‐
corticoid for 7 days. Participants in the standard-dose group will continue at 50, 60 or 75
mg/day for 7 additional days and taper to between 12.5 and 20 mg/day at 3 months and 5 mg/
day at 6 months. Participants in the low-dose group will continue at 25, 30 or 40 mg/day for 7
days and taper to between 6 and 10 mg/day by 3 months and 5 mg/day by 6 months.
All patients will receive 5 mg/day from 6 months to 12 months after randomisation.
Safety: Multiple adverse consequences of steroid therapy are recognized, including weight gain
and fat redistribution, fluid retention and hypertension, irritability and difficulty sleeping,
cataracts and glaucoma, elevated blood sugars and skin thinning. It is critical to minimize
steroid exposure while suppressing disease activity. It is common practice to prescribe therapy
to reduce the risk of glucocorticoid-induced osteoporosis. Vitamin D supplementation and
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Calcium intake should fall in line with local treatment recommendations, and bisphosphonates
are typically necessary for patients as they will be exposed to prolonged steroid use. Additional
considerations are prophylaxis against opportunistic infections such as Pneumocystis jiroveci
with Trimethoprim/Sulfamethoxazole (T/S), and stress-dose steroids for critical illness.
5.2. Induction of remission in generalized and severe AAV
5.2.1. Cyclophosphamide
Efficacy: Cyclophosphamide is typically reserved for patients with severe or generalized AAV,
or if a poor prognostic factor is present. In 1973, Fauci and Wolff published their experience
of treating 18 patients with GPA and systemic involvement with oral cyclophosphamide [21].
Twelve patients achieved remission, and 6 were able to discontinue immunosuppression after
several months. They later reported on a larger cohort of 85 patients with GPA treated with a
protocol of oral cyclophosphamide of 2 mg/kg/day and high dose prednisone of 1 mg/kg /day
[22]. They were followed prospectively over 21 years with 93% achieving complete remission
and a mean survival of 48 months although 29% relapsed. This work also highlighted the
toxicity of this drug, such as gonadal failure, cystitis in 34% of patients, and 1 patient devel‐
oping lymphoma.
In an effort to reduce the toxicity associated with the prolonged used of cyclophosphamide,
Hoffman et al [23] designed a protocol of intravenous pulses, similar to the National Institute
of Health (NIH) study of treatment of severe lupus nephritis [24]. Fourteen patients with GPA,
12 with relapsing disease previously treated with daily oral cyclophosphamide, received
monthly pulses of 1g/m2 of cyclophosphamide for 6 months along with high dose oral
glucocorticoids. If remission was achieved the pulses were reduced in frequency to every 2
months for 6 months then every 3 months for a total of 1.5 years. Glucocorticoids were tapered
and stopped over this time period. Unfortunately, although 93% improved initially, only 21%
had sustained remission. Thirty six percent (4 patients) had experienced toxicity, mostly
attributable to infections, but confounded by the concomitant use of high doses of prednisone.
A subsequent 18 month European open-label randomized controlled multicenter clinical trial,
CYCLOPS [16], of pulse versus daily oral cyclophosphamide in 149 newly diagnosed patients
with AAV (including GPA, MPA and renal limited vasculitis) with renal involvement and a
creatinine between 150 and 500 umol/L was performed. Patients in the intravenous pulse group
received cyclophosphamide 15 mg/kg every 2 weeks for the first 3 pulses then continued either
intravenous pulse (15 mg/kg) or oral pulse (5 mg/kg for 3 consecutive days), every 3 weeks
afterwards until remission and then for another 3 months. The oral cyclophosphamide group
received 2 mg/kg daily until remission then 1.5 mg/kg for another 3 months. Remission
maintenance was with azathioprine at a dose of 2 mg/kg for 18 months. The cyclophosphamide
doses were adjusted for renal function and age, as well as leukocyte count, with a maximum
dose of 1.2 g in the pulse group and 200 mg in the daily oral group. Both groups were also
treated with oral glucocorticoids during induction, with initially 1 mg/kg (maximum 80 mg)
used, but with progressive tapering to 12.5 mg at 3 months and 5 mg at 18 months.
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The administration route of cyclophosphamide did not affect the remission rate, with 88% of
subjects randomized to pulse therapy and 88% of subjects randomized to daily oral therapy
in remission at 9 months. Both groups had a median time to remission of 3 months (range of
0.5 to 8 months in the pulse group and 1 to 7.5 months in the daily oral group). The cumulative
dose in the oral group was higher than the pulse group (median 15.9 g vs. 8.2 g) with a lower
rate of leukopenia in the pulse group.
The long-term follow-up of these studies was recently reported [25]. Retrospective chart
information was available for 134 out of 148 patients, and 1 patient was subsequently excluded
as their diagnosis was changed to EGPA. The median follow-up was 4.3 years. An increased
relapse rate was observed in the pulse group compared to the daily oral group. Fifteen (20.8%)
of the daily oral group and 30 (39.5%) of the pulse group had at least one relapse. However
there was no difference in survival, renal function nor adverse events between groups. The
presence of PR3-ANCA was independently associated with an increase risk of relapse (hazard
ratio 2.47 (95%CI 1.32-4.59, p=0.004).
A meta-analysis [26] of randomized trials [27-29] comparing daily oral versus intravenous
pulse of cyclophosphamide concluded that pulse therapy was significantly less likely to fail
in remission induction (odds ratio (OR) 0.29 (95% CI 0.12-0.73) and had a significantly lower
risk of infection (OR: 0.45 (95% CI 0.23-0.89)) and leucopenia (OR 0.36 (95% CI 0.17-0.78)). There
was a non-significant increase in the relapse odds in the pulse cyclophosphamide group (OR
1.79 (95%CI 0.85-3.75).
Safety: Although cyclophosphamide has been the mainstay of treatment for generalized and
severe forms of AAV, there are several limitations to its use. First, there are significant adverse
events associated with this drug even at the lower cumulative dose achieved through pulse
therapy. Infertility is a concern in individuals of childbearing age, and bladder toxicity and
malignancy are associated with increased morbidity and mortality [30-32]. The development
of leukopenia significantly increases the risk of bacterial infection, and renders the patient
susceptible to opportunistic infections. Table 2 provides dose adjustment recommendations
based on the patient’s age, renal function and leukocyte nadir to reduce the risk of toxicity.
5.2.2. Rituximab
Efficacy: The use of Rituximab, an anti-CD20 monoclonal antibody depleting B lymphocytes,
has been reported in several case series and case reports to be effective in patients with
generalized, severe and refractory disease [33]. This was subsequently confirmed by 2
randomized controlled trials published in 2010, “Rituximab in ANCA-associated Vasculitis”
(RAVE) [19] and “Randomised Trial of Rituximab Versus Cyclophosphamide for Generalized
ANCA-Associated Vasculitis” (RITUXVAS) [34]. In these two studies rituximab was non-
inferior and/or equivalent to cyclophosphamide in inducing remission in AAV. Rituximab was
superior to cyclophosphamide in relapsing patients.
RAVE [19] was a North American multicentre, randomized, double blind, controlled thera‐
peutic trial where 197 patients with new or relapsing ANCA positive GPA and MPA without
severe renal disease (creatinine less than 354 umol/L) or severe alveolar hemorrhage (not
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requiring a ventilator). The study was designed as a non-inferiority trial comparing intrave‐
nous rituximab (375 mg/m2 of body surface weekly for 4 weeks) to daily oral cyclophospha‐
mide (2mg/kg). Both groups received methylprednisolone 1 g for one to three pulses, followed
by prednisone 1 mg/kg. The primary end point was defined as a Birmingham Vasculitis
Activity Score for Wegener’s Granulomatosis (BVAS/WG) [35] of 0 and the complete discon‐
tinuation of prednisone at 6 months. Once remission was achieved by 3 to 6 months, mainte‐
nance therapy was initiated in the cyclophosphamide group with azathioprine (2 mg/kg),
however the Rituximab group did not receive maintenance therapy. There was no difference
in the primary outcome at 6 months between the 2 groups. Sixty-three of the 99 patients in the
rituximab group (64%) reached the primary end point, as compared with 52 of 98 in the control
group (53%), and met the criterion for non-inferiority (P<0.001). However, among patients with
relapsing disease at baseline, rituximab was more efficacious than cyclophosphamide, with 34
of 51 patients in the rituximab group (67%) reaching the primary end point, as compared with
only 21 of 50 in the control group (42%) (p=0.01). In an oral presentation at the American
College of Rheumatology Annual Meeting in November 2011, the extended follow-up to 18
months was reported. One single course of rituximab without maintenance therapy was as
effective as 18 months of induction and maintenance therapy with cyclophosphamide followed
by azathioprine. Complete remission was achieved and sustained at 6, 12, and 18 months in
64%, 47%, and 39% of subjects in the rituximab arm, comparable at 53%, 39%, and 33% of
subjects in the cyclophosphamide/azathioprine arm, respectively. Disease flares in the two
treatment arms did not differ in number or severity, and no unexpected safety issues were
detected. Patients at highest risk for flare had GPA, were PR3 positive, were without major
renal disease, and had relapsing disease at baseline. Disease flares in the rituximab treated
subjects occurred only after the return of detectable levels of B cells.
RITUXVAS [34]  was  a  European multicenter,  open label,  randomized trial  of  rituximab
compared to intravenous cyclophosphamide in 44 patients with newly diagnosed ANCA-
associated vasculitis with renal involvement [34]. Subjects in the rituximab group received both





Max dose: 1.2 g
>60: reduce dose by
2.5 mg/kg per pulse
>70: reduce dose by
5 mg/kg per pulse
300 to 500 μmol/L
(3.4 to 5.7 mg/dL)
reduce pulse by 2.5
mg/kg
2 to 3 x109/L reduce
dose of subsequent
pulse by 20%






Max dose: 200 mg
>60 reduce dose by
25%
>70 reduce dose by
50%
< 4x109/L stop drug
until >4
reduce dose by 25%
<1x109/L restart at
50 mg then increase
weekly as tolerated
Table 2. Adjusted cyclophosphamide dose according to age, renal function and leukocyte count [16]
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rituximab (375 mg/m2 per week for 4 consecutive weeks) and intravenous cyclophosphamide
(15 mg/kg) with the first and third rituximab infusions. They did not receive any maintenance
therapy. If they had progressive disease within the first 6 months, a third dose of intravenous
cyclophosphamide was permitted. Subjects in the control group received intravenous cyclophos‐
phamide (15 mg/kg), every 2 weeks for the first three doses then every 3 weeks for 3 to 6 months
until remission, followed by azathioprine for maintenance. Both treatment arms received 1 g of
intravenous methylprednisolone and then oral prednisone at 1 mg/kg per day initially, with a
reduction to 5 mg per day at the end of 6 months. The primary outcome was sustained remis‐
sion and rates of serious adverse events at 12 months. Thirty-three subjects were enrolled in the
rituximab group and 11 in the control group. Sustained remission was observed in 25 of 33
patients in the rituximab group (76%) and 9 of 11 patients in the control group (82%) (p=0.68).
Six of the 33 subjects in the rituximab group (18%) and 2 of the 11 patients in the control group
(18%) died. Among the survivors, sustained remission rates at 12 months were equal, and
observed in 93% of the rituximab group and 90% of the control group (p = 0.80). The median time
to remission was 90 days (interquartile range, 79 to 112) in the rituximab group and 94 days
(interquartile range, 91 to 100) in the control group (p=0.87). At 12 months of follow-up, 4 of 27
subjects in the rituximab group (15%) and 1 of 10 subjects in the control group (10%) suffered a
relapse (p=0.70). This study also demonstrated efficacy in serious renal disease. Among the 9
subjects who were on dialysis at study entry, 6 of the 8 subjects randomized to the rituximab
group attained sustained remission, and 5 no longer required dialysis.
Safety: Unfortunately, rituximab use was not associated with a lower rate of serious adverse
events in either study, although there were more episodes of leukopenia in subjects random‐
ized to cyclophosphamide. In the RAVE study, there were no significant differences between
the treatment groups in the numbers of total adverse events, serious adverse events, or non
−disease related adverse events. During the first 6 months of the trial, solid malignant tumors
were diagnosed in 1 patient in each group; 2 patients in the control group and 1 in the rituximab
group died. Six malignant conditions developed in 5 additional patients after 6 months. Four
of those patients had been assigned initially to rituximab and one had been assigned to
cyclophosphamide. Among patients with exposure to rituximab during the trial, malignant
conditions developed in 6 of 124 (5%), as compared with 1 of 73 patients without exposure to
rituximab (1%, p=0.26). In RITUXVAS, severe adverse events were similar between groups
(rituximab group 42% and 36% in the standard care group). Infection rates were similar
(rituximab group incidence rate 0.66/patient year vs 0.60/patient year in the standard care
group). Dialysis patients were particular prone to adverse events, with 3 of the 9 dying, and 7
of 9 with at least one serious adverse event.
5.2.3. Plasma exchange
The  rationale  for  the  physical  removal  of  ANCA  by  plasma  exchange  is  based  on  the
demonstration  of  the  pathogenic  role  of  ANCA  in  animal  models  of  AAV  [36,  37].
Corticosteroids and cyclophosphamide are used concomitantly to suppress inflammation
and autoantibody production.
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A  study  of  patients  with  severe  renal  involvement  of  GPA  and  MPA  causing  rapidly
progressive glomerulonephritis was designed to compare intravenous (IV) methylpredniso‐
lone and plasma exchange [38]. One hundred and thirty-seven patients with creatinine >500
umol/l were enrolled in this open label, randomized trial and 69% were on dialysis for less
than 2 weeks at study entry. Both groups received oral cyclophosphamide (2.5 mg/kg/day
reduced to  1.5  mg/kg/day at  3  months and stopped at  6  months),  followed by azathio‐
prine (2 mg/kg/day). Oral prednisolone was tapered from 1 mg/kg/day at entry to 0.25 mg/
kg/day  by  week  10,15  mg/day  at  3  months  and10mg/day  from  5  to12  months.  The  IV
methylprednisolone group (n=67)  received 1000 mg/day for  three consecutive days,  and
the  subjects  in  the  plasma  exchange  group  (n=70)  underwent  a  total  of  seven  plasma
exchanges within 14 days of study entry, with a plasma exchange volume of 60 ml/kg on
each occasion and volume replacement with 5% albumin mandated in the protocol.  The
primary outcome measure was renal  recovery at  3  months,  defined by patient  survival,
dialysis independence, and serum creatinine <500 umol/l (5.8 mg/dl).
There  was  a  significant  decrease  in  the  risk  of  end-stage  renal  disease  in  the  plasma
exchange group compared to IV methylprednisolone but there was no significant differ‐
ence  in  patient  survival  at  12  months.  By 3  months,  renal  recovery had occurred in  33
(49%) of 67 of the IV methylprednisolone group and 48 (69%) of 70 of the plasma exchange
group (95%CI for the difference 18 to 35%; p = 0.02). This effect was sustained to 12 months
from entry with only two from each group progressing to end stage renal  disease after
initial recovery, with a risk reduction of 24% (95%CI 6.1 to 41) at 12 months. At 12 months,
43% of  subjects  in the IV methylprednisolone group and 59% of  subjects  in the plasma
exchange group remained alive and independent of dialysis (p = 0.008). The hazard ratio
for end stage renal disease over 12 months for plasma exchange versus IV methylpredniso‐
lone was 0.47 (95%CI 0.24 to 0.91; p = 0.03). Subject survival at 3 and 12 months respective‐
ly was 84% and 76% in the IV methylprednisolone group and 84% and 73% in the plasma
exchange group (log rank test p = 0.68). Mortality was 25.5% at 12 months, and the major
causes of death were infection (n = 19), pulmonary hemorrhage (n = 6), and cardiovascu‐
lar disease (n = 4).  Most deaths occurred during the first  3 months,  when corticosteroid
dosages were highest and vasculitis was most active. After 3 months, there was a higher
mortality in those who had failed to recover renal function.
5.3. Induction of remission in early systemic disease
5.3.1. Methotrexate
The treatment of AAV with cyclophosphamide is associated with significant toxicity and
morbidity as previously discussed. Alternative immunosuppression to reduce this risk have
been  studied.  The  “Non-Renal  Wegener’s  Granulomatosis  Treated  Alternatively  with
Methotrexate” (NORAM) [17] trial was designed to test the hypothesis than methotrexate
could replace cyclophosphamide for remission induction. NORAM was a non-inferiority,
unblinded,  prospective,  randomized,  controlled  trial  in  early  systemic  GPA  and  MPA,
without organ-threatening or life-threatening disease and a creatinine of less than 150 umol/
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L. More than 90% of patients had GPA. In total, 49 subjects were treated with methotrex‐
ate (15 mg/week orally escalating to a maximum of 20–25 mg/week by 12 weeks), which
was then maintained until month 10 and then tapered and discontinued by month 12. A
total  of  46  subjects  received  oral  cyclophosphamide  (2  mg/kg/day  (maximum  150  mg/
day) until remission), for a minimum of 3 and a maximum of 6 months. Dose alterations
were made for subjects >60 years of age, and the drug was withdrawn if the total white
blood cell  count fell  below 4 x109/liter.  At remission,  cyclophosphamide was reduced to
1.5 mg/kg/day until month 10, when it was tapered and discontinued by month 12. Both
treatment  groups  received  oral  prednisolone  1  mg/kg/day,  tapered  to  15  mg/day  at  12
weeks and 7.5  mg/day by 6  months,  and discontinued by 12 months.  The primary end
point  was  induction  of  remission  within  6  months.  Between  month  12  to  18,  patients
received no immunosuppressant agents.
At 6 months,  90% of subjects randomized to methotrexate and 94% of subjects random‐
ized to cyclophosphamide achieved remission (p=0.041). The median time to remission was
3 months (range 1–9) in the methotrexate group and 2 months (range 1–5) in the cyclophos‐
phamide group (p=0.19 log rank test). Of the subjects who achieved remission during the
treatment  period,  70% of  the  subjects  randomized to  methotrexate  and 47% of  subjects
randomized to cyclophosphamide had a relapse, with the time to relapse being significant‐
ly longer in the cyclophosphamide group (median 15 months, range 4-17) compared to the
methotrexate group (median 13 months, range 2-17) (P =0.023 log rank test). Leukopenia
was  more  common  in  the  cyclophosphamide  group  and  liver  dysfunction  was  more
common in the methotrexate group.
The long term follow-up of patients treated in the NORAM study was recently reported [39].
Data was obtained on all 95 original subjects with a median duration of follow-up of 6 years.
Subjects in the methotrexate group required a longer duration of corticosteroid therapy during
the trial period of 18 months (median 15 months, interquartile range (IQR) 12-18) compared
to 12 months (IQR 12-15) in the cyclophosphamide group, p=0.005). During subsequent follow-
up, the median duration of corticosteroid therapy during months 19-60 was 3.0 years in the
methotrexate group and only 1.5 years in the cyclophosphamide group (p=0.004). After the
trial period of 18 months, patients’ treatment was left at the discretion of their physicians.
Physicians were asked to provide information regarding drugs used to manage disease flare
such as cyclophosphamide, methotrexate, azathioprine and mycophenolate mofetil. Exposure
to cyclophosphamide and these other agents was also longer in the methotrexate group
(p=0.037; and p=0.031, respectively).
Overall, the cumulative relapse-free survival from the time of first remission was 69% after 1
year, 32% after 3 years, and 24% after 5 years of follow-up, demonstrating a trend to being
higher in the cyclophosphamide group (p=0.056, logrank test). The cumulative overall survival
did not differ between treatment arms (p=0.88, log-rank test) and was 98% after 1 year, 93%
after 3 years, and 89% after 5 years. The number of serious infections did not differ between
treatment groups. The authors have concluded that methotrexate therapy was associated with
less effective long-term disease control as compared to cyclophosphamide.
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6. Maintenance of remission
The relapse rate of AAV is high, as demonstrated by the different induction trials, and occur
frequently during a drug withdrawal period [32, 39]. Therefore it is important to maintain
long-term immunosuppression, while limiting drug toxicity. When a standardized treatment
of induction of remission followed by maintenance therapy is applied, the relapse rate in GPA
can be reduced from 76.8% (in cohorts treated before 1993) to 50% (in cohorts treated after
1999) over 5 years follow-up [40]. Several studies have provided different drug alternatives
for maintenance of remission.
6.1. Azathioprine
An 18 month prospective open label study (CYCAZAREM) compared the use of oral cyclo‐
phosphamide to azathioprine in the maintenance phase, with 155 subjects with GPA, MPA
and renal limited vasculitis recruited from 39 hospitals in 11 European countries [41]. All
subjects had received the same remission-induction therapy, consisting of daily oral cyclo‐
phosphamide (2 mg/kg) and prednisolone (initially 1 mg/kg/day, with the dose tapered to 0.25
mg/kg/day by 12 weeks). Renal vasculitis was the most common form of organ involvement,
occurring in 94 percent of the patients in the study. Patients attaining remission by 3 months,
and those attaining remission between 3 and 6 months, were randomly assigned to treatment
with azathioprine (2 mg/kg/day) or to continue cyclophosphamide therapy at a lower dose
(1.5 mg/kg/day). Both treatment groups continued to receive prednisolone 10 mg daily. At 12
months after study entry, both groups received azathioprine at a dose of 1.5 mg/kg/day and
prednisolone 7.5 mg daily. The primary end point was relapse, either major (threatened
function of the kidney, lung, brain, eye, motor nerve or gut) or minor (affecting at least three
other items in the Birmingham Vasculitis Activity Score (BVAS)) [42].
Of the initial 155 subjects, clinical remission was achieved in 93% overall, with 77% reaching
this target by 3 months and 16% between 3 and 6 months. These patients were randomly
assigned to cyclophosphamide (73 patients) or azathioprine (71 patients). Azathioprine was
demonstrated to be equivalent to cyclophosphamide for maintenance therapy. Sixteen percent
in the azathioprine group had relapses, compared to 14% in the cyclophosphamide group
(p=0.65). Five patients in each group had a major relapse. The most frequent adverse event was
neutropenia (55% of patients, including the remission and maintenance phase), with 52% of
infections occurring during an episode of neutropenia. There was no difference in renal
outcomes between the groups, with renal failure occurring in only 3% of patients.
6.2. Methotrexate
A prospective, open-label, multicenter trial, comparing methotrexate and azathioprine for
maintenance of remission in GPA and MPA (WEGENT) was designed to detect treatment
tolerance [43]. Three-quarters of the patients had GPA. Sixty-three patients who had achieved
remission with intravenous cyclophosphamide and corticosteroids received oral azathioprine
(2 mg/kg/day) and 63 received methotrexate (initial 0.3 mg/kg/week, progressively increased
to 25 mg per week) for 12 months. At the end of the scheduled maintenance therapy period,
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azathioprine and methotrexate were withdrawn over a period of 3 months at the discretion of
the treating physician. T/S was recommended for 2 additional years for patients with GPA
after discontinuation of the maintenance immunosuppressive agents. The primary end point
was an adverse event requiring discontinuation of the study drug or causing death.
At the censoring date for analysis, the mean follow-up after randomization was 29 months.
Adverse events leading to the primary end point (i.e., discontinuation of the study drug or
death) occurred in 11% of the azathioprine group and 19% in the methotrexate group (p=0.21).
After starting maintenance therapy, 46% of azathioprine recipients had at least one adverse
event as compared with 56% of methotrexate recipients (p= 0.29). Thirty-six percent of
azathioprine subjects and 33% of methotrexate subjects had a relapse (p=0.71). In 73% of the
patients the relapse occurred after discontinuation of the drugs. This study demonstrated that
the two agents were equivalent in safety and also efficacy. There was a trend toward a higher
risk of adverse events with methotrexate, with a hazard ratio of 1.65 (95%CI, 0.65-4.18).
6.3. Mycophenolate mofetil
Mycophenolate mofetil is a prodrug of mycophenolic acid, which is a reversible inhibitor of
inosine monophosphate dehydrogenase in guanosine nucleotide synthesis, upon which T and
B cells are dependent, and has cytostatic effects on lymphocytes [44]. It has been proposed as
a less toxic alternative to azathioprine and has been evaluated in one randomized trial. The
IMPROVE study was an open-label trial to assess whether mycophenolate mofetil reduces the
risk of relapse compared with azathioprine in patients with AAV in remission [45]. All patients
received cyclophosphamide (daily oral or intermittent intravenous doses for a maximum of 6
months) and glucocorticoids (up to 3 g of methylprednisolone over 3 days was allowed for
severe disease, then 1 mg/kg/day (maximum 80 mg) of oral prednisolone) for induction of
remission. Plasma exchange could also be used for severe disease. Oral steroids were reduced
according to a standardized schedule to 15 mg/day at the start of the remission regimen,
tapered to 5 mg/day after 12 months, and were withdrawn after 24 months. One hundred and
fifty six patients with a new diagnosis of GPA and MPA were enrolled after remission was
achieved. The azathioprine group (n=80) initially received 2 mg/kg/day (maximum 200 mg),
with dose reductions to 1.5 mg/kg/day after 12 months and 1 mg/kg/day after 18 months, with
drug withdrawal after 42 months. Seventy-six patients assigned to the mycophenolate mofetil
group received 2 g/day, which was reduced to 1500 mg/day after 12 months, 1000 mg/day after
18 months, and withdrawn after 42 months. The primary end point was relapse-free survival,
defined as the time from remission to the first relapse (major or minor), withdrawal, death or
loss to follow-up, or the end of the follow-up period.
Median follow-up for both treatment groups from start of maintenance therapy was 39 months.
Relapses were more common in the mycophenolate mofetil group. In total, 55% of the
mycophenolate mofetil recipients experienced relapses (18 major, 24 minor), as compared to
38% of azathioprine recipients (10 major, 20 minor), with an unadjusted hazard ratio for
mycophenolate mofetil use of 1.69 (95%CI, 1.06-2.70; p=0.03) at 4 years. The risk of severe
adverse events was not significantly different between groups, with a hazard ratio of 0.53
(95%CI, 0.23-1.18, p=0.12). Therefore mycophenolate mofetil should not be considered as a first
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choice for maintenance of remission in AAV, but could be used in situations of intolerance or
contraindication to azathioprine.
6.4. Leflunomide
Leflunomide is a disease-modifying agent commonly used in the treatment of rheumatoid
arthritis as an alternative to methotrexate. A prospective randomized controlled trial of
leflunomide compared to methotrexate in patients with generalized GPA for maintenance of
remission was conducted in 5 German rheumatology centres [46]. The study was powered to
find equivalence between the 2 drugs. Patients achieving complete or partial remission with
daily oral cyclophosphamide (2mg/kg) and prednisolone and maintained remission for at least
3 months were enrolled in the study. Partial remission was defined as partial improvement of
the disease persisting for at least 3 months represented by a constant disease extent index and
BVAS. Complete remission was defined as the absence of pathological findings in clinical,
radiological and serological investigations, irrespective of the ANCA titre. Twenty-eight
subjects received oral methotrexate starting at a dose of 7.5 mg/week, increased over 9 weeks
to 20 mg/week. Folic acid 10 mg weekly was taken the day after methotrexate. Twenty-six
patients received leflunomide with a loading dose of 100 mg daily for 3 days, followed by 20
mg daily and then increased to 30 mg daily after 4 weeks. Prednisone was allowed at a dose
of 10mg/day or less, and was tapered by 2.5mg/month in the absence of disease activity until
a dose of 5 mg was reached, and then by 1 mg/month thereafter. The primary efficacy outcome
was the number of major and minor relapses.
In the leflunomide group, 23% of subjects experienced a relapse, compared to 46% of metho‐
trexate subjects (p=0.09), and the incidence of major relapses was significantly higher in the
methotrexate group (p=0.037). The study was terminated prematurely in September 2003 after
the advisory board had decided that the high rate of major relapses in the methotrexate group
was not acceptable.
Safety: There was no significant difference in the number of adverse events between the groups.
Thirty-four adverse events were observed in the leflunomide group and 17 in the methotrexate
group (p=0.09). Leflunomide was stopped in two patients with intractable hypertension, one
patient with peripheral neuropathy and one patient with leucopenia, whereas no patient
stopped due to adverse events in the methotrexate group. Twenty-five infectious episodes, 13
in the leflunomide group and 12 in the methotrexate group were noted, all responding well to
conventional antibiotic treatment on outpatient basis.
7. Refractory/relapsing disease
Some patients have disease that proves to be refractory to the therapies used for induction and
maintenance of remission as above. Typically, patients with lung and upper airway involve‐
ment, positive PR3-ANCA and severe renal involvement have more resistant disease [47-49].
Relapse is also frequent in AAV, with an overall risk of 38% at 5 years seen in a large cohort
of 535 patients from 70 European trial sites between 1995 and 2002 [32]. The presence of positive
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PR3 ANCA, cardiac involvement and absence of severe renal disease at presentation was found
to be a predictor of relapse in that group [9]. A variety of agents have been proposed to address
these refractory cases.
7.1. Tumor necrosis factor inhibition
7.1.1. Etanercept
The “Wegener’s Granulomatosis Etanercept Trial” (WGET) was a randomized, double blind,
placebo controlled trial of etanercept as an adjunct to conventional therapy in patients with
GPA [18]. The study enrolled 181 patients from 8 centres in the United States. Patients had
newly diagnosed or relapsing GPA with a BVAS/WG of ≥3 and either limited or severe
manifestations of their disease. Etanercept at the dose of 25 mg twice weekly subcutaneously
or placebo was used simultaneously at the time of randomization with conventional therapy
(corticosteroids along with methotrexate for limited disease and oral cyclophosphamide
followed by methotrexate for severe disease induction and azathioprine for maintenance) and
maintained as the conventional drugs were tapered over time. Prednisone was tapered by a
specific protocol to be completely discontinued within six months, assuming that no relapse
occurred.
The primary outcome measure was sustained disease remission, defined as a BVAS/WG of 0,
for at least six months. The median duration of treatment was 25 months for etanercept and
19 months for placebo and the mean duration of follow-up was 27 months in the overall cohort.
Seventy percent of subjects in the etanercept group met the primary outcome, as compared
with 75% in the control group (p=0.39). There was no significant difference between groups in
the time to sustained remission. The overall rate of sustained remission throughout follow-up
was only 49.4%. Disease flares during treatment were not significantly different between the
etanercept and control groups (relative risk, 0.89 (95%CI 0.62 to 1.28; p=0.54). The major
concern arising from this study however was in the development of adverse events. Moder‐
ately severe to fatal infections occurred in 49% of subjects and were equal between treatment
groups, however six solid cancers were identified during the trial, and all occurred in the
etanercept group (standardized incidence ratio of 3.12 (95%CI 1.15–6.80, p=0.014)). An
additional 3 other patients were subsequently diagnosed with a solid malignancy within 6
months of completion of the trial [50]. This study clearly demonstrated that etanercept was
not effective, and the use of etanercept in combination with cyclophosphamide is associated
with an increased risk of malignancy.
7.1.2. Infliximab and adalimumab
Infliximab has been studied as an adjuvant therapy for induction of remission in new, relapsing
and refractory disease. A prospective, open label, multicenter study in the United Kingdom
evaluated 2 small groups of patients with active disease [51]. In the new presentation or relapse
group, infliximab (5 mg/kg) was given at 0, 2, 6 and 10 weeks as an adjuvant therapy to oral
cyclophosphamide (2mg/kg/day) for 14 weeks and prednisolone. Once remission was
achieved the cyclophosphamide was replaced by azathioprine (2 mg/kg/day, reduced to 1.5
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mg/kg/day after 1 year) or mycophenolate mofetil if azathioprine wasn’t tolerated. In patients
with persistent disease despite the use of methotrexate, azathioprine, mycophenolate mofetil
or T/S, infliximab (5 mg/kg) at 0, 2, 6 and 10 weeks was added. If remission was achieved
infliximab was maintained every 6 weeks for 1 year. In both groups, 88% achieved remission
(BVAS ≤1) within a mean of 6.4 weeks. During follow-up (mean 17 months), only 18%
experienced a relapse of disease. Both groups were able to significantly reduce their gluco‐
corticoid dose from a mean of 24 mg/day to 9 mg/day at week 14. There were 2 deaths in the
newly diagnosed and relapsing group and 21% had severe infections. A second study has also
examined infliximab use (5 mg/kg at 0, 2, 6 and 10 weeks) in addition to standard therapy and
found no effect [52]. At 1 year, time to achieve remission, remission rates, adverse events,
damage index scores, and relapse rates were similar between groups.
Adalimumab was used as an adjunctive therapy in a single centre, open label, prospective,
uncontrolled study of newly diagnosed patients with GPA or MPA with renal involvement
[53]. Seventy-nine percent of patients achieved remission (BVAS = 0) within the first 14 weeks
of the study, and the mean oral prednisolone dose decreased from 37 to 8 mg/day, demon‐
strating potential efficacy but requiring further rigorous study.
7.2. Rituximab
Smith et al [54] reported a retrospective study of maintenance therapy with Rituximab in 73
patients with refractory or relapsing GPA and MPA. Twenty-eight received treatment with a
single dose of rituximab (1000 mg) at the time of relapse. Of these, 19 were subsequently
retreated at 6 months intervals. Another 45 patients were treated with rituximab (1000 mg
twice at an interval of 2 weeks) and then received treatment (1000 mg) every 6 months for 24
months with ongoing follow-up for an additional 24 months. Of the patients treated with a
single 1000 mg dose at relapse, 73% relapsed within 24 months. The frequency of relapse was
lower in patients who received retreatment at 6 months at only 11% (p<0.001), and in those
treated with the higher initial dose and ongoing retreatment at 12% (p<0.001). At 48 months,
relapses had occurred in 81% of the single dose group, compared to 26% and 39% in the group
with retreatment and the higher initial dose and retreatment. The median time to first relapse
was 12 months (range 5-76) in the group receiving the single dose, compared to 29 months
(range 5-48) in the group receiving retreatment and 34.5 months (range 5-53) in the group with
the higher initial dose and retreatment. Retreatment was associated with a reduction in relapse
rates compared to single rituximab courses and allowed early withdrawal of immunosup‐
pression and glucocorticoid reduction or withdrawal. In this study B cell count and ANCA
positivity didn’t correlate with the time of relapse.
7.3. Intravenous immunoglobulin (IVIg)
IVIg consists of intact IgG molecules, representing all IgG subclasses, from the pooled plasma
of donors [55]. Small amounts of IgM, IgA, HLA and cytokines are also present in the prepa‐
ration. As such, IVIg contains a broad range of immune antibodies against pathogens and
foreign antigens. Proposed mechanisms of action include modulation of the expression and
function of Fc receptors, interference with the activation of complement and the cytokine
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network, provision of antiidiotypic antibodies (idiotypes are located in the variable region of
autoantibodies in autoimmune conditions), and effects on the activation, differentiation and
effector functions of both T and B cells [55]. In vasculitis, IVIG may reverse monocyte and
neutrophil activation, reduce autoantibody production or effect the autoreactive T cell function
[56]. In vitro, incubation of ANCA vasculitis patient sera with IVIg inhibited ANCA activity
[57] which provided evidence to proceed with clinical use of this agent.
In the initial publication, 7 patients with long-standing ANCA vasculitis resistant to standard
immunosuppressive therapy received IVIg at a dose of 0.4 g/kg/day for 5 days [58] with
maintenance of steroids and cytotoxic drugs for at least 6 weeks following the infusions. All
patients improved within 2 days to 3 weeks; 5 went into full remission, 1 had sustained
improvement and 1 had a partial transient response within 8 weeks. Relapses occurred in 3
patients between 2 and 9 months after treatment, with no relapses documented in the others
who were followed between 6 and 18 months. Other successful case reports, case series and
open-label studies followed [59-64] describing positive treatment responses, however there is
likely an element of publication bias and confounding due to the variety in disease presenta‐
tions, prior and concomitant immunosuppressive therapies received, variable steroid doses
and the lack of a control arm for comparison. Jayne et al reported on a prospective double-
blind placebo-controlled multicentre randomized study targeting a reduction in the BVAS [65].
Patients had either GPA or MPA with active vasculitis despite 2 months of treatment with
prednisolone and cyclophosphamide or azathioprine. The mean disease duration of subjects
in this study was 52.5 months. Seventeen subjects were randomized to receive IVIg 0.4
g/kg/day for 5 days with no changes in immunosuppressive drugs for 3 months after the trial
infusion, and 17 subjects were in the placebo arm. Patients were assessed 2 weeks following
the infusion and then monthly until 12 months. A 50% reduction in the BVAS was observed
in 14/17 of the IVIg group and 6/17 of the placebo group respectively (OR 8.56; 95%CI 1.74-42.2,
p-0.015) and two subjects in the placebo group died within 3 months. The mean BVAS in the
IVIg group at baseline was 6.1, with a BVAS reduction of 3.2 at 1 month and 4.1 at 3 months,
compared to a baseline BVAS of 5.4 in the placebo group with reductions of 0.87 and 2.3 at 1
and 3 months. However, after 3 months there were no significant differences in the BVAS
between groups or in the frequency of relapse (5/16 for IVIG and 4/15 for placebo), and no
differences in the subsequent steroids or immunosuppressive doses in follow-up.
An open-label study enrolled 22 poor-prognosis patients experiencing a relapse of WG or MPA
despite treatment or within 1 year of stopping corticosteroids and/or immunosuppressants
(0.5 g/kg/day for 4 days) to monthly IVIg for 6 months [66]. Temporary increases in prednisone
doses were allowed but other immunosuppressants had to be maintained during the 6 months
of IVIg therapy but could then be reduced, discontinued or switched to maintenance agents if
cyclophosphamide had been given. In this study, the mean disease duration was 27 months
(range 7-109 months) and the median BVAS 2005 at study entry was 11 (range 3-25). All but 1
patient was receiving steroids and/or immunosuppressants. Between months 1 and 5, 21
subjects achieved remission, with complete remission in 73% at 6 months, partial remission in
9% and relapse in 14%. The effect seemed persistent, with 13/16 responders still in complete
remission at 9 months, and with 12/16 in complete remission at month 24. In those achieving
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complete remission at month 9, steroids were stopped in 4 and reduced in 9, with reductions
in other immunosuppressants in 4 subjects. The median BVAS 2005 was 0 (range 0-13) at month
9 and 0 (range 0-12) at month 24. Moderate and transient effects of IVIg were reported including
nausea, headaches, fever, arthralgias, and 1 patient developed renal insufficiency and was
deemed a treatment failure.
IVIg is a safe agent for use in particular clinical situations, such as pregnancy, those with a
potential infection mimicking vasculitis, and for patients with refractory persistent disease
despite traditional immunsuppressive agents. Adverse effects included headaches, rise in
creatinine, aseptic meningitis, backache and fever/chills. Theoretical adverse effects include
the transmission of blood-borne pathogens, although extensive screening of blood donors
occurs. Randomized clinical trials are lacking, and the role in new-onset disease or specific
ANCA vasculitis entities is unexplored. The current evidence base is considered poor given
the open-label nature of the literature with a lack of a control arm data or control over
concomitant treatments received in addition of IVIg.
7.4. 15-deoxyspergualin (DSG; 1-amino-19-guanidino-11-hydroxy-4,9,12-triazanona-
decane-10,1-3-dione; gusperimus)
DSG is a synthetic analogue of spergualin, a natural product of the bacterium Bacillus latero‐
sporus, which possesses immunosuppressive properties [67, 68]. DSG has effects on B cell
differentiation, blocks kappa light-chain expression at the transcriptional level and acts on T
effector cells. A pilot study of DSG (0.5 mg/kg daily subcutaneously to target a leukocyte nadir
of 3000/μ, 6 cycles with 2 week recovery periods) was performed in 20 subjects with refractory
WG or MPA [68]. Steroids were dosed at the discretion of the treating physician but no other
immunosuppressives were allowed. The primary endpoint was remission (either complete
remission with no signs of disease activity, or partial remission defined as no new activity but
with minor persistent activity) after 6 cycles of DSG. Response was noted in 14 subjects (6
complete, 8 partial, with the mean BVAS improving from 11 (SD 5.8) to 4 (2.9) in responders,
and a reduction of oral steroids from 30 mg per day to 7.5 mg/day. Response was maintained
out to 6 months for 11/14 of the responders. Side effects were largely infectious in nature, with
diarrhea, headache, bronchitis, and anemia also reported. In a further open label-study, 44
patients with refractory WG received DSG (0.5 mg/kg/day in six cycles of 21 days with 7 days
between cycles) followed by azathioprine [69]. In this study, 20 patients achieved remission
(BVAS of 0 for 2 months) and 22 achieved partial remission (BVAS <50% of entry score).
7.5. Alemtuzumab (campath-1H)
The humanized monoclonal antibody, anti-CD52 (alemtuzumab, CAMPATH-1H) depletes
circulating lymphocytes and macrophages. It has shown a promising effect in patients with
multiple sclerosis and Behçet’s disease. It has been studied in a group of patients with relapsing
and refractory GPA or MPA in one UK centre [70]. Patients were eligible to receive CAM‐
PATH-1H if they had multiple relapses or life threatening disease despite the standard of care.
Prednisolone was continued at 10 mg/day but all other immunosuppressants were discontin‐
ued. CAMPATH-1H was administered intravenously on consecutive days at doses of 4, 10,
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40, 40 and 40 mg, for a total dose of 134 mg. CAMPATH-1H was readministered for relapsing
disease if the initial treatment was tolerated. A total of 71 patients were treated and followed
for a mean of 5 years. Sixty-five percent of patients achieved clinical remission, and an
additional 20% had a clinically significant improvement in disease activity but still required
greater than 10 mg of prednisolone per day or an additional immunosuppressive agent to
control disease activity. Almost all subjects relapsed after 9 months, with better renal function
and the absence of neurologic involvement protective for relapse. Unfortunately, 44% of the
cohort died during the follow-up period, 5 patients were diagnosed with malignancy, and 11%
developed Graves disease. These adverse events may limit the use of alemtuzumab in practice
to highly selected patients or those with disease refractory to all other agents.
7.6. Antithymocyte globulin (ATG)
The SOLUTION protocol was an uncontrolled prospective open-label study of ATG in 15
subjects with refractory GPA [71]. ATG was given intravenously at a dose of 2.5 mg/kg for a
mean of 2 doses. The authors describe partial remission in 9/15 subjects and complete remission
in 4/15 with reduced prednisone requirements (mean 49 mg/day to 13 mg/day) and only
experiencing relapse after 8 months. However, 2 patients died and 5 others developed severe
infections.
8. Treatment of localized vasculitis
8.1. Trimethoprim/sulfamethoxazole (T/S)
There have been case reports and case series of patients with AAV limited to the upper and/or
lower respiratory tract treated with T/S for induction of remission with a good outcome [72]. A
study of 72 patients with GPA looked at the role of T/S for induction of remission in the localized
stage, and maintenance of remission in the generalized stage [73]. Nineteen patients with
localized disease received T/S (2×960 mg/day) with 58% achieving complete or partial remis‐
sion for a median of 43 months. Patients with generalized disease in remission did poorly with
T/S, with 42% of those treated with T/S alone relapsing after a median of 13 months compared
to a relapse rate of 29% at a median of 23 months in the patients not receiving T/S.
T/S was found to be superior to placebo in maintaining remission in a prospective, placebo
controlled study of 81 patients with GPA, 41 of whom received T/S after induction of remission
of generalized disease [74]. At 24 months of follow-up 82% of patients in the T/S group were
still in remission, as compared to only 60% in the placebo group, with a relative risk of relapse
of 0.40 (95%CI 0.17 to 0.98). This reduction was especially evident with respect to relapses
involving the upper airways.
Therefore, T/S can be considered for the induction of remission of localized GPA but patients
should be monitored carefully for signs of progression to systemic disease. The efficacy of
maintenance of remission in generalized disease is controversial and currently not the
recommended standard of practice.
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9. Treatment of eosinophilic granulomatosis with polyangiitis (Churg-
Strauss syndrome)
Most of the studies in AAV include only a small number of patients with EGPA or exclude
them altogether. We will discuss trials performed specifically in EGPA.
9.1. EGPA with poor prognosis
A prospective, multicenter, randomized trial of patients newly diagnosed with EGPA and
at least  1  poor prognosis factor (creatinine >140 μmol/l  (1.58 mg/dl);  proteinuria >1 gm/
day; or central nervous system, gastrointestinal, or myocardial involvement) was conduct‐
ed to determine the shortest immunosuppressant duration able to limit the occurrence of
side effects and still induce and maintain disease remission by comparing glucocorticoids
and 6 compared to 12 intravenous cyclophosphamide pulses [75]. All patients received 3
consecutive  intravenous  pulses  of  methylprednisolone  (15  mg/kg)  followed  by  oral
prednisone  (1  mg/kg/day)  for  3  weeks  followed  by  a  tapering  regime.  Intravenous
cyclophosphamide (0.6 g/m2) was given every 2 weeks for 1 month, then every 4 weeks,
and  patients  were  randomized  to  receive  either  6  or  12  cyclophosphamide  pulses.  The
cumulative cyclophosphamide dose was twice as high in the 12-pulse group than in the
6-pulse group (6.6  g/m2  versus 3.48 g/m2).  There was a  non-significant  difference in the
proportion  of  patients  achieving  complete  remission,  at  91%  for  the  group  receiving  6
pulses and 84% for the group receiving 12 pulses. Relapse frequency demonstrated a trend
to significance at 74% for the group receiving 6-pulses compared to 62% in the 12-pulse
group (p=0.07),  and the  mean time to  first  relapse  was  268  days  in  the  12-pulse  group
compared to 222 days in the 6-pulse group, although this was not statistically different.
Adverse events and deaths were equal between both groups.
9.2. EGPA without poor prognosis factor
One study examined treatment efficacy of corticosteroids as first-line treatment of EGPA
without  poor  prognosis  factors,  and  the  use  of  azathioprine  compared  to  intravenous
cyclophosphamide for treatment failure or relapse [76].  Subjects  could receive 1 intrave‐
nous pulse of methylprednisolone (15 mg/kg) and then oral prednisone (1 mg/kg/day for
3 weeks) followed by a tapering regimen. If the prednisone could not be tapered below 20
mg,  or  if  the  patient  experienced  a  relapse,  they  were  randomized  to  azathioprine  (2
mg/kg/day  for  6  months)  or  6  cyclophosphamide  doses  (0.6  g/m2  every  2  weeks  for  1
month, then every 4 weeks). Ninety-three percent of subjects achieved remission, with a 1
year  survival  rate  of  100%  and  5  year  survival  rate  of  97%.  Of  the  subjects  achieving
remission,  37% relapsed,  and 3% could not  reduce  their  prednisone.  A total  of  19  sub‐
jects  went  onto  randomization  with  10  receiving  cyclophosphamide  and  9  receiving
azathioprine.  Fifty  percent  of  the  cyclophosphamide  subjects  achieved  remission,  com‐
pared to 78% of the azathioprine subjects. Low-dose corticosteroid therapy was required
in 79% of subjects long-term, primarily due to lung disease.




The treatment of AAV is directed at achieving disease control to prevent morbidity and
mortality, while minimizing treatment toxicity. Corticosteroid use remains critical in rapidly
achieving disease activity suppression, whereas cyclophosphamide and rituximab regimens
should be reserved for induction of severe generalized disease, and plasma exchange for severe
renal disease. In less severe cases of systemic disease methotrexate is suitable for remission
induction. Maintenance of remission is achieved preferably with azathioprine or methotrexate,
with leflunomide, mycophenolate mofetil and cyclophosphamide remaining as options.
Finally, new discoveries and research will certify the role of alternative agents, such as
monoclonal anti-tumor necrosis factor therapy, IVIg, DSG, ATG and CAMPATH-1, in
refractory disease.
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